首页 > 最新文献

Perfusion-Uk最新文献

英文 中文
The effect of air-free administration of intravenous drugs on microemboli during cardiopulmonary bypass. 心肺旁路过程中无空气静脉注射药物对微栓子的影响。
IF 1.1 4区 医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-01 Epub Date: 2024-02-29 DOI: 10.1177/02676591241236892
Amber den Ouden, Marco C Stehouwer, Bernd Geurts, Erik Hofman, Peter Bruins

Objective: During cardiopulmonary bypass (CPB), gaseous microemboli (GME) that originate from the extracorporeal circuit are released into the arterial blood stream of the patient. Gaseous microemboli may contribute to adverse outcome after cardiac surgery with CPB. Possibly, air may be collected in the right atrium during induction of anesthesia and released during CPB start. The aim of this study was to assess if the GME load entering the venous line of the CPB circuit could be reduced by training of anesthesia personal in avoiding air introduction during administration of intravenous medication.

Methods: In 94 patients undergoing coronary artery bypass grafting with CPB, GME number and volume were measured intraoperatively with a bubble counter (BCC300). The quantity and the relationship between GME number and volume in the venous and arterial line were determined in 2 periods before and after education of the anesthesiologists and nurses.

Results: In the venous line no significant differences were observed between numbers and volumes of GME between groups. Comparing patients with low versus high GME load, showed significantly more patients from the intervention group in the low GME-load group, namely 29 versus 18. Administration of medication by anesthesia was confirmed as a clear cause of GME/air-introduction into the venous circulation. Scavenging properties of the CPB circuit including the oxygenator showed a 99.9% reduction of GME.

Conclusions: A wide spread of GME generation during perfusion was present with no difference in generation of GME between groups. Lower GME load observed in patients (intervention group) and examples of air introduction during drug administration suggest that air introduced by anesthesia contributes to the GME load during CPB. Scavenging properties of the CPB circuit contribute very much to patient safety regarding reduction of venous air. Awareness and education create the possibilities for further reduction of GME during cardiopulmonary bypass.

目的:在心肺旁路(CPB)过程中,源自体外循环的气体微栓子(GME)会释放到患者的动脉血流中。气体微栓子可能会导致使用 CPB 进行心脏手术后出现不良预后。可能是在麻醉诱导时空气聚集在右心房,并在 CPB 启动时释放出来。本研究旨在评估是否可以通过对麻醉人员进行培训,避免在静脉注射药物时引入空气,从而减少进入 CPB 循环静脉管路的 GME 负荷:方法:在94名接受CPB冠状动脉旁路移植术的患者中,使用气泡计数器(BCC300)在术中测量GME的数量和体积。结果:在对麻醉师和护士进行教育之前和之后的两个阶段,分别测定了静脉和动脉管路中 GME 的数量和体积以及两者之间的关系:在静脉管路中,各组之间的 GME 数量和体积没有明显差异。比较GME负荷低与GME负荷高的患者,结果显示干预组中GME负荷低的患者明显多于GME负荷高的患者,前者为29例,后者为18例。麻醉用药被证实是导致 GME/空气进入静脉循环的明确原因。CPB回路(包括氧合器)的清除特性显示,GME减少了99.9%:结论:灌注过程中产生的 GME 分布广泛,各组间产生的 GME 没有差异。在患者(干预组)中观察到的较低 GME 负荷以及在给药过程中引入空气的例子表明,麻醉时引入的空气是 CPB 期间 GME 负荷的一部分。在减少静脉空气方面,心肺复苏术回路的清除特性对患者安全大有裨益。提高认识和教育为进一步减少心肺旁路术中的 GME 创造了可能性。
{"title":"The effect of air-free administration of intravenous drugs on microemboli during cardiopulmonary bypass.","authors":"Amber den Ouden, Marco C Stehouwer, Bernd Geurts, Erik Hofman, Peter Bruins","doi":"10.1177/02676591241236892","DOIUrl":"10.1177/02676591241236892","url":null,"abstract":"<p><strong>Objective: </strong>During cardiopulmonary bypass (CPB), gaseous microemboli (GME) that originate from the extracorporeal circuit are released into the arterial blood stream of the patient. Gaseous microemboli may contribute to adverse outcome after cardiac surgery with CPB. Possibly, air may be collected in the right atrium during induction of anesthesia and released during CPB start. The aim of this study was to assess if the GME load entering the venous line of the CPB circuit could be reduced by training of anesthesia personal in avoiding air introduction during administration of intravenous medication.</p><p><strong>Methods: </strong>In 94 patients undergoing coronary artery bypass grafting with CPB, GME number and volume were measured intraoperatively with a bubble counter (BCC300). The quantity and the relationship between GME number and volume in the venous and arterial line were determined in 2 periods before and after education of the anesthesiologists and nurses.</p><p><strong>Results: </strong>In the venous line no significant differences were observed between numbers and volumes of GME between groups. Comparing patients with low versus high GME load, showed significantly more patients from the intervention group in the low GME-load group, namely 29 versus 18. Administration of medication by anesthesia was confirmed as a clear cause of GME/air-introduction into the venous circulation. Scavenging properties of the CPB circuit including the oxygenator showed a 99.9% reduction of GME.</p><p><strong>Conclusions: </strong>A wide spread of GME generation during perfusion was present with no difference in generation of GME between groups. Lower GME load observed in patients (intervention group) and examples of air introduction during drug administration suggest that air introduced by anesthesia contributes to the GME load during CPB. Scavenging properties of the CPB circuit contribute very much to patient safety regarding reduction of venous air. Awareness and education create the possibilities for further reduction of GME during cardiopulmonary bypass.</p>","PeriodicalId":49707,"journal":{"name":"Perfusion-Uk","volume":" ","pages":"398-405"},"PeriodicalIF":1.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139991594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Normalizing Anti-Thrombin III for heparin management during routine cardiopulmonary bypass for congenital cardiothoracic surgery: A single institution practice review. 先天性心胸手术常规心肺旁路过程中肝素管理的抗凝血酶 III 正常化:单一机构实践回顾。
IF 1.1 4区 医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-01 Epub Date: 2024-03-19 DOI: 10.1177/02676591241239819
Joseph Deptula, Vincent Olshove, Molly Oldeen, Deborah Kozik, Bahaaldin Alsoufi
<p><strong>Introduction: </strong>Over the past decade, there has been an increase in the use of recombinant Anti-Thrombin III (AT-III) administration during neonatal and pediatric short- and long-term mechanical support for the replacement of acquired deficiencies. Recombinant AT-III (Thrombate) administration is an FDA licensed drug indicated primarily for patients with hereditary deficiency to treat and prevent thromboembolism and secondarily to prevent peri-operative and peri-partum thromboembolism. Herein we propose further use of Thrombate for primary AT-III deficiency of the newborn as well as for acquired dilution and consumption secondary to cardiopulmonary bypass (CPB).</p><p><strong>Methodology: </strong>All patients undergoing CPB obtain a preoperative AT-III level. Patients with identified deficiencies are normalized in the OR using recombinant AT-III as a patient load, in the CPB prime, or both. Patient baseline Heparin Dose Response (HDR) is assessed using the Heparin Management System (HMS) before being exposed to AT-III. If a patient load of AT-III is given, a second HDR is obtained and this AT-III Corrected HDR is used as the primary goal during CPB. Once CPB is initiated, an AT-III level is obtained with the first patient blood analysis. A subtherapeutic level results in an additional dose of AT-III. During the rewarm period, a final AT-III level is obtained and AT-III treated once again if subtherapeutic. A retrospective, matched analysis review of practice analyzing two groups, a Study Group (Repeat HDR, May 2022 onward) and Matched Group (Without Repeat HDR, July 2019 to April 2022), for age (D), weight (Kg) and operation was conducted. The focus of the study was to determine any change in heparin sensitivity identified post AT-III patient bolus load in the HDR (U/mL), Slope (U/mL/s), ACT (s), and total amount of heparin on CPB (U) and protamine (mg) used in each group.</p><p><strong>Results: </strong>No significance was seen in Baseline AT-III (%), post heparin load HDR (U/mL), first CPB ACT (s), first CPB HDR (U/mL), or total CPB heparin (u/Kg) between the two groups. Statistical significance was seen in Baseline ACT (s), Baseline HDR (U/mL), Baseline Slope (U/mL/s), Post Heparin Load ACT (s), first CPB AT-III (%), and Protamine (mg/Kg) (<i>p</i> < .05). No statistical significance was seen in the Study Intragroup between pre versus post AT-III patient load baseline sample in ACT (s), however significance was seen in HDR (U/mL) and Slope (U/mL/s) (<i>p</i> < .05).</p><p><strong>Conclusion: </strong>Implementation of AT-III monitoring and therapy before and during CPB in conjunction with the HMS allows patients to maintain a steady state of anticoagulation with overall less need for excessive heparin replacement and potentially thrombin activation. The result is obtaining a steady state of anticoagulation, a reduced fluctuation in the heparin and ACT levels and a potential for lower co-morbidities associated with prolonged
导言:过去十年来,在新生儿和儿童短期和长期机械支持过程中使用重组抗凝血酶 III(AT-III)替代后天性缺乏症的情况越来越多。重组 AT-III(凝血酶原)是美国食品及药物管理局(FDA)许可的药物,主要用于治疗和预防遗传性凝血酶原缺乏症患者的血栓栓塞,其次用于预防围手术期和围产期血栓栓塞。在此,我们建议进一步使用血栓通治疗新生儿原发性 AT-III 缺乏症以及心肺旁路术(CPB)继发的获得性稀释和消耗:方法:所有接受 CPB 的患者都要进行术前 AT-III 检测。方法:所有接受 CPB 的患者都会在术前检测 AT-III 水平。已确定存在缺陷的患者将在手术室内使用重组 AT-III 作为患者负荷,或在 CPB 原液中使用重组 AT-III 作为患者负荷,或两者兼用。在使用 AT-III 之前,使用肝素管理系统 (HMS) 评估患者的基线肝素剂量反应 (HDR)。如果患者使用了 AT-III,则会获得第二次 HDR,并将此 AT-III 校正 HDR 作为 CPB 期间的主要目标。一旦开始 CPB,将在第一次患者血液分析时获得 AT-III 水平。低于治疗水平将导致额外的 AT-III 剂量。在再热期间,将获得最终的 AT-III 水平,如果低于治疗水平,则再次进行 AT-III 治疗。研究人员对两组患者的年龄(D)、体重(Kg)和手术情况进行了回顾性、匹配分析回顾,即研究组(2022 年 5 月起重复 HDR)和匹配组(2019 年 7 月至 2022 年 4 月未重复 HDR)。研究的重点是确定 AT-III 患者栓剂负荷后肝素敏感性在 HDR(U/mL)、Slope(U/mL/s)、ACT(s)以及 CPB 上肝素总量(U)和各组使用的原胺(mg)方面的变化:两组的基线 AT-III(%)、肝素负荷后 HDR(U/mL)、首次 CPB ACT(秒)、首次 CPB HDR(U/mL)和 CPB 肝素总量(u/Kg)均无显著性差异。基线 ACT (s)、基线 HDR (U/mL)、基线斜率 (U/mL/s)、肝素负荷后 ACT (s)、首次 CPB AT-III (%) 和丙胺 (mg/Kg) 均有统计学意义(P < .05)。在研究组内,AT-III 患者负荷前与负荷后基线样本之间的 ACT(秒)无统计学意义,但 HDR(U/mL)和斜率(U/mL/s)有意义(P < .05):结论:在 CPB 前和 CPB 期间结合 HMS 实施 AT-III 监测和治疗可使患者保持稳定的抗凝状态,总体上减少了过量肝素替代和潜在凝血酶激活的需要。其结果是获得稳定的抗凝状态,减少肝素和 ACT 水平的波动,并有可能降低与 CPB 时间延长相关的并发症。
{"title":"Normalizing Anti-Thrombin III for heparin management during routine cardiopulmonary bypass for congenital cardiothoracic surgery: A single institution practice review.","authors":"Joseph Deptula, Vincent Olshove, Molly Oldeen, Deborah Kozik, Bahaaldin Alsoufi","doi":"10.1177/02676591241239819","DOIUrl":"10.1177/02676591241239819","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Over the past decade, there has been an increase in the use of recombinant Anti-Thrombin III (AT-III) administration during neonatal and pediatric short- and long-term mechanical support for the replacement of acquired deficiencies. Recombinant AT-III (Thrombate) administration is an FDA licensed drug indicated primarily for patients with hereditary deficiency to treat and prevent thromboembolism and secondarily to prevent peri-operative and peri-partum thromboembolism. Herein we propose further use of Thrombate for primary AT-III deficiency of the newborn as well as for acquired dilution and consumption secondary to cardiopulmonary bypass (CPB).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methodology: &lt;/strong&gt;All patients undergoing CPB obtain a preoperative AT-III level. Patients with identified deficiencies are normalized in the OR using recombinant AT-III as a patient load, in the CPB prime, or both. Patient baseline Heparin Dose Response (HDR) is assessed using the Heparin Management System (HMS) before being exposed to AT-III. If a patient load of AT-III is given, a second HDR is obtained and this AT-III Corrected HDR is used as the primary goal during CPB. Once CPB is initiated, an AT-III level is obtained with the first patient blood analysis. A subtherapeutic level results in an additional dose of AT-III. During the rewarm period, a final AT-III level is obtained and AT-III treated once again if subtherapeutic. A retrospective, matched analysis review of practice analyzing two groups, a Study Group (Repeat HDR, May 2022 onward) and Matched Group (Without Repeat HDR, July 2019 to April 2022), for age (D), weight (Kg) and operation was conducted. The focus of the study was to determine any change in heparin sensitivity identified post AT-III patient bolus load in the HDR (U/mL), Slope (U/mL/s), ACT (s), and total amount of heparin on CPB (U) and protamine (mg) used in each group.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;No significance was seen in Baseline AT-III (%), post heparin load HDR (U/mL), first CPB ACT (s), first CPB HDR (U/mL), or total CPB heparin (u/Kg) between the two groups. Statistical significance was seen in Baseline ACT (s), Baseline HDR (U/mL), Baseline Slope (U/mL/s), Post Heparin Load ACT (s), first CPB AT-III (%), and Protamine (mg/Kg) (&lt;i&gt;p&lt;/i&gt; &lt; .05). No statistical significance was seen in the Study Intragroup between pre versus post AT-III patient load baseline sample in ACT (s), however significance was seen in HDR (U/mL) and Slope (U/mL/s) (&lt;i&gt;p&lt;/i&gt; &lt; .05).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Implementation of AT-III monitoring and therapy before and during CPB in conjunction with the HMS allows patients to maintain a steady state of anticoagulation with overall less need for excessive heparin replacement and potentially thrombin activation. The result is obtaining a steady state of anticoagulation, a reduced fluctuation in the heparin and ACT levels and a potential for lower co-morbidities associated with prolonged ","PeriodicalId":49707,"journal":{"name":"Perfusion-Uk","volume":" ","pages":"431-439"},"PeriodicalIF":1.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140177428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to "Direct aortic cannulation versus femoral arterial cannulation for early outcomes in acute type A aortic dissection: A study-level meta-analysis". 主动脉直接插管与股动脉插管对急性 A 型主动脉夹层早期预后的影响:研究层面的荟萃分析"。
IF 1.1 4区 医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-01 Epub Date: 2024-08-23 DOI: 10.1177/02676591241264128
{"title":"Corrigendum to \"Direct aortic cannulation versus femoral arterial cannulation for early outcomes in acute type A aortic dissection: A study-level meta-analysis\".","authors":"","doi":"10.1177/02676591241264128","DOIUrl":"10.1177/02676591241264128","url":null,"abstract":"","PeriodicalId":49707,"journal":{"name":"Perfusion-Uk","volume":" ","pages":"529"},"PeriodicalIF":1.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of fetal hemoglobin in the artificial placenta: A premature ovine model. 胎儿血红蛋白在人工胎盘中的作用:早产绵羊模型
IF 1.1 4区 医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-01 Epub Date: 2024-03-22 DOI: 10.1177/02676591241240725
Brianna L Spencer, Brian P Fallon, Jennifer S McLeod, Marie Cornell, Erin E Perrone, David M Manthei, Alvaro Rojas-Peña, Ronald B Hirschl, Robert H Bartlett, George B Mychaliska

Introduction: A radical paradigm shift in the treatment of premature infants failing conventional treatment is to recreate fetal physiology using an extracorporeal Artificial Placenta (AP). The aim of this study is to evaluate the effects of changing fetal hemoglobin percent (HbF%) on physiology and circuit function during AP support in an ovine model.

Methods: Extremely premature lambs (n = 5) were delivered by cesarean section at 117-121 d estimated gestational age (EGA) (term = 145d), weighing 2.5 ± 0.35 kg. Lambs were cannulated using 10-14Fr cannulae for drainage via the right jugular vein and reinfusion via the umbilical vein. Lambs were intubated and lungs were filled with perfluorodecalin to a meniscus with a pressure of 5-8 cm H2O. The first option for transfusion was fetal whole blood from twins followed by maternal red blood cells. Arterial blood gases were used to titrate AP support to maintain fetal blood gas values.

Results: The mean survival time on circuit was 119.6 ± 39.5 h. Hemodynamic parameters and lactate were stable throughout. As more adult blood transfusions were given to maintain hemoglobin at 10 mg/dL, the HbF% declined, reaching 40% by post operative day 7. The HbF% was inversely proportional to flow rates as higher flows were required to maintain adequate oxygen saturation and perfusion.

Conclusions: Transfusion of adult blood led to decreased fetal hemoglobin concentration during AP support. The HbF% was inversely proportional to flow rates. Future directions include strategies to decrease the priming volume and establishing a fetal blood bank to have blood rich in HbF.

简介在治疗常规治疗失败的早产儿方面,一个根本性的范式转变是利用体外人工胎盘(AP)重建胎儿的生理机能。本研究的目的是在绵羊模型中评估胎儿血红蛋白百分比(HbF%)的变化对人工胎盘支持过程中生理和回路功能的影响:极早产羔羊(n = 5)于估计胎龄(EGA)117-121 d(足月 = 145 d)时经剖腹产分娩,体重为 2.5 ± 0.35 kg。羔羊使用 10-14Fr 插管经右颈静脉引流,再经脐静脉回输。给羔羊插管,用全氟萘烷充填肺部至半月板,压力为 5-8 cm H2O。首先输注的是双胞胎的胎儿全血,然后是母体红细胞。使用动脉血气滴定 AP 支持以维持胎儿血气值:血液动力学参数和乳酸在整个过程中保持稳定。随着输注更多成人血液以维持血红蛋白在 10 mg/dL 的水平,HbF% 有所下降,在术后第 7 天达到 40%。HbF% 与流速成反比,因为需要更高的流速来维持足够的血氧饱和度和血流灌注:结论:在 AP 支持期间,输注成人血液会导致胎儿血红蛋白浓度下降。HbF%与流速成反比。未来的发展方向包括减少引血量和建立胎儿血库以获得富含 HbF 的血液。
{"title":"The role of fetal hemoglobin in the artificial placenta: A premature ovine model.","authors":"Brianna L Spencer, Brian P Fallon, Jennifer S McLeod, Marie Cornell, Erin E Perrone, David M Manthei, Alvaro Rojas-Peña, Ronald B Hirschl, Robert H Bartlett, George B Mychaliska","doi":"10.1177/02676591241240725","DOIUrl":"10.1177/02676591241240725","url":null,"abstract":"<p><strong>Introduction: </strong>A radical paradigm shift in the treatment of premature infants failing conventional treatment is to recreate fetal physiology using an extracorporeal Artificial Placenta (AP). The aim of this study is to evaluate the effects of changing fetal hemoglobin percent (HbF%) on physiology and circuit function during AP support in an ovine model.</p><p><strong>Methods: </strong>Extremely premature lambs (<i>n</i> = 5) were delivered by cesarean section at 117-121 d estimated gestational age (EGA) (term = 145d), weighing 2.5 ± 0.35 kg. Lambs were cannulated using 10-14Fr cannulae for drainage via the right jugular vein and reinfusion via the umbilical vein. Lambs were intubated and lungs were filled with perfluorodecalin to a meniscus with a pressure of 5-8 cm H<sub>2</sub>O. The first option for transfusion was fetal whole blood from twins followed by maternal red blood cells. Arterial blood gases were used to titrate AP support to maintain fetal blood gas values.</p><p><strong>Results: </strong>The mean survival time on circuit was 119.6 ± 39.5 h. Hemodynamic parameters and lactate were stable throughout. As more adult blood transfusions were given to maintain hemoglobin at 10 mg/dL, the HbF% declined, reaching 40% by post operative day 7. The HbF% was inversely proportional to flow rates as higher flows were required to maintain adequate oxygen saturation and perfusion.</p><p><strong>Conclusions: </strong>Transfusion of adult blood led to decreased fetal hemoglobin concentration during AP support. The HbF% was inversely proportional to flow rates. Future directions include strategies to decrease the priming volume and establishing a fetal blood bank to have blood rich in HbF.</p>","PeriodicalId":49707,"journal":{"name":"Perfusion-Uk","volume":" ","pages":"460-465"},"PeriodicalIF":1.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11416565/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140194939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of oxygen delivery during cardiopulmonary bypass on postoperative neurological outcomes in patients undergoing cardiac surgery: A scoping review of the literature. 心肺旁路术中氧气输送对心脏手术患者术后神经功能预后的影响:文献综述。
IF 1.1 4区 医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-01 Epub Date: 2024-03-14 DOI: 10.1177/02676591241239279
Abdelrahman Elsebaie, Ayesha Shakeel, Shetuan Zhang, Marianne Alarie, Mohamed El Tahan, Mohammad El-Diasty

Background: Reduced oxygen delivery (DO2) during cardiopulmonary bypass (CPB) was proposed as a risk factor for the development of postoperative neurological complications (PONCs), including cerebrovascular accidents (CVA), delirium, and postoperative cognitive dysfunction (POCD). We aimed to review the current evidence on the association between intraoperative DO2 and the incidence of PONCs.

Methods: MEDLINE, Embase, the Cochrane Library, and Web of Science were electronically searched to identify comparative studies from inception until July 2023 that reported the association between intraoperative DO2 levels and the incidence of PONCs (as defined by the scales and diagnostic tools utilized by the studies' authors) in adults patients undergoing cardiac surgery using CPB.

Results: Of the 2513 papers identified, 10 studies, including 21,875 participants, were included. Of these, three studies reported on delirium, two on POCD, and five on CVA. Eight studies reported reduced intraoperative DO2 in patients who developed delirium and CVA. There was a lack of consensus on the cut-off of DO2 levels or the correlation between the period below these threshold values and the development of PONC.

Conclusions: Limited data suggest that maintaining intraoperative DO2 above the critical threshold levels and ensuring adequate intraoperative cerebral perfusion may play a role in minimizing the incidence of neurological events in adult patients undergoing cardiac surgery on cardiopulmonary bypass.

背景:心肺旁路术(CPB)期间氧输送(DO2)减少被认为是术后神经系统并发症(PONC)发生的风险因素,包括脑血管意外(CVA)、谵妄和术后认知功能障碍(POCD)。我们旨在回顾术中 DO2 与 PONCs 发生率之间关系的现有证据:对 MEDLINE、Embase、Cochrane 图书馆和 Web of Science 进行了电子检索,以确定从开始到 2023 年 7 月报告了使用 CPB 进行心脏手术的成人患者术中 DO2 水平与 PONCs(由研究作者使用的量表和诊断工具定义)发生率之间关系的比较研究:在已确定的 2513 篇论文中,共纳入了 10 项研究,包括 21,875 名参与者。其中,3 项研究报告了谵妄,2 项研究报告了 POCD,5 项研究报告了 CVA。八项研究报告了发生谵妄和 CVA 的患者术中 DO2 降低的情况。对于 DO2 水平的临界值或低于这些临界值的时间与发生 PONC 之间的相关性缺乏共识:有限的数据表明,将术中 DO2 维持在临界阈值水平以上并确保术中有足够的脑灌注可能有助于最大限度地降低在心肺旁路下接受心脏手术的成年患者的神经事件发生率。
{"title":"Effect of oxygen delivery during cardiopulmonary bypass on postoperative neurological outcomes in patients undergoing cardiac surgery: A scoping review of the literature.","authors":"Abdelrahman Elsebaie, Ayesha Shakeel, Shetuan Zhang, Marianne Alarie, Mohamed El Tahan, Mohammad El-Diasty","doi":"10.1177/02676591241239279","DOIUrl":"10.1177/02676591241239279","url":null,"abstract":"<p><strong>Background: </strong>Reduced oxygen delivery (DO<sub>2</sub>) during cardiopulmonary bypass (CPB) was proposed as a risk factor for the development of postoperative neurological complications (PONCs), including cerebrovascular accidents (CVA), delirium, and postoperative cognitive dysfunction (POCD). We aimed to review the current evidence on the association between intraoperative DO<sub>2</sub> and the incidence of PONCs.</p><p><strong>Methods: </strong>MEDLINE, Embase, the Cochrane Library, and Web of Science were electronically searched to identify comparative studies from inception until July 2023 that reported the association between intraoperative DO<sub>2</sub> levels and the incidence of PONCs (as defined by the scales and diagnostic tools utilized by the studies' authors) in adults patients undergoing cardiac surgery using CPB.</p><p><strong>Results: </strong>Of the 2513 papers identified, 10 studies, including 21,875 participants, were included. Of these, three studies reported on delirium, two on POCD, and five on CVA. Eight studies reported reduced intraoperative DO<sub>2</sub> in patients who developed delirium and CVA. There was a lack of consensus on the cut-off of DO<sub>2</sub> levels or the correlation between the period below these threshold values and the development of PONC.</p><p><strong>Conclusions: </strong>Limited data suggest that maintaining intraoperative DO<sub>2</sub> above the critical threshold levels and ensuring adequate intraoperative cerebral perfusion may play a role in minimizing the incidence of neurological events in adult patients undergoing cardiac surgery on cardiopulmonary bypass.</p>","PeriodicalId":49707,"journal":{"name":"Perfusion-Uk","volume":" ","pages":"283-294"},"PeriodicalIF":1.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140133100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Concomitant interventions in mitral valve surgery - A European perspective. 二尖瓣手术中的并发症干预 - 欧洲视角。
IF 1.1 4区 医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-01 Epub Date: 2024-03-02 DOI: 10.1177/02676591241237130
Vinci Naruka, Arian Arjomandi Rad, Jacob Chacko, Guiqing Liu, Jonathan Afoke, Prakash P Punjabi

Introduction: In recent years, major findings on concomitant procedures and anticoagulation management have occurred in Mitral Valve (MV) surgery. Therefore, we sought to evaluate the current practices in MV interventions across Europe.

Methods: In October 2021, all national cardio-thoracic societies in the European region were identified following an electronic search and sent an online survey of 14 questions to distribute among their member consultant/attending cardiac surgeons.

Results: The survey was completed by 91 consultant/attending cardiac surgeons across 12 European countries, with 78% indicating MV repair as their specialty area. 57.1% performed >150 operations/year and 71.4% had 10+ years of experience.Concomitant tricuspid valve repair is performed for moderate tricuspid regurgitation (TR) by 69% of surgeons and for mild TR by 26.3%, both with annular diameter >40 mm. 50.6% indicated ischaemic MV surgery in patients undergoing CABG if moderate mitral regurgitation with ERO >20 mm2 and regurgitant volume >30 mL, and 45.1% perform it if severe MR with ERO >40 mm2 and regurgitant volume >60 mL. For these patients the preferred management was: MVR if predictors of repair failure identified (47.2%) and downsizing annuloplasty ring only (34.1%).For atrial fibrillation (AF) in cardiac surgery, 34.1% perform ablation with biatrial lesion and 20% with left sided only. 62.6% perform concomitant Left Atrial Appendage (LAA) Occlusion irrespective of AF ablation with a left atrial clip. A wide variability in anticoagulation strategies for MV repair and bioprosthetic MV valve was reported both for patients in sinus rhythm and AF.

Conclusion: These results demonstrate a variable practice for MV surgery, and a degree of lack of compliance with surgical intervention guidelines and anticoagulation strategy.

导言:近年来,二尖瓣手术在并发症和抗凝管理方面取得了重大发现。因此,我们试图评估欧洲各国目前在二尖瓣介入治疗方面的做法:2021 年 10 月,我们通过电子搜索确定了欧洲地区所有国家的心胸外科协会,并向其会员顾问/主治心脏外科医生发送了一份包含 14 个问题的在线调查问卷:12 个欧洲国家的 91 名心脏外科顾问/主治医生完成了调查,78% 的人表示中风修补术是他们的专业领域。69%的外科医生对中度三尖瓣反流(TR)进行了三尖瓣修复术,26.3%的外科医生对轻度TR进行了三尖瓣修复术,两者的瓣环直径均大于40毫米。如果中度二尖瓣反流的ERO>20 mm2且反流容量>30 mL,50.6%的外科医生会为接受CABG手术的患者实施缺血性中上瓣手术;如果重度二尖瓣反流的ERO>40 mm2且反流容量>60 mL,45.1%的外科医生会为患者实施缺血性中上瓣手术。对于这些患者,首选的治疗方法是对于心脏手术中的心房颤动(AF)患者,34.1%的患者进行了双房病变消融术,20%的患者仅进行了左房病变消融术。无论是否使用左心房夹进行房颤消融,62.6%的患者会同时进行左心房阑尾(LAA)封堵术。窦性心律和房颤患者的中风修复和生物修复中风瓣抗凝策略差异很大:这些结果表明,中上瓣手术的做法各不相同,在一定程度上没有遵守手术干预指南和抗凝策略。
{"title":"Concomitant interventions in mitral valve surgery - A European perspective.","authors":"Vinci Naruka, Arian Arjomandi Rad, Jacob Chacko, Guiqing Liu, Jonathan Afoke, Prakash P Punjabi","doi":"10.1177/02676591241237130","DOIUrl":"10.1177/02676591241237130","url":null,"abstract":"<p><strong>Introduction: </strong>In recent years, major findings on concomitant procedures and anticoagulation management have occurred in Mitral Valve (MV) surgery. Therefore, we sought to evaluate the current practices in MV interventions across Europe.</p><p><strong>Methods: </strong>In October 2021, all national cardio-thoracic societies in the European region were identified following an electronic search and sent an online survey of 14 questions to distribute among their member consultant/attending cardiac surgeons.</p><p><strong>Results: </strong>The survey was completed by 91 consultant/attending cardiac surgeons across 12 European countries, with 78% indicating MV repair as their specialty area. 57.1% performed >150 operations/year and 71.4% had 10+ years of experience.Concomitant tricuspid valve repair is performed for moderate tricuspid regurgitation (TR) by 69% of surgeons and for mild TR by 26.3%, both with annular diameter >40 mm. 50.6% indicated ischaemic MV surgery in patients undergoing CABG if moderate mitral regurgitation with ERO >20 mm<sup>2</sup> and regurgitant volume >30 mL, and 45.1% perform it if severe MR with ERO >40 mm<sup>2</sup> and regurgitant volume >60 mL. For these patients the preferred management was: MVR if predictors of repair failure identified (47.2%) and downsizing annuloplasty ring only (34.1%).For atrial fibrillation (AF) in cardiac surgery, 34.1% perform ablation with biatrial lesion and 20% with left sided only. 62.6% perform concomitant Left Atrial Appendage (LAA) Occlusion irrespective of AF ablation with a left atrial clip. A wide variability in anticoagulation strategies for MV repair and bioprosthetic MV valve was reported both for patients in sinus rhythm and AF.</p><p><strong>Conclusion: </strong>These results demonstrate a variable practice for MV surgery, and a degree of lack of compliance with surgical intervention guidelines and anticoagulation strategy.</p>","PeriodicalId":49707,"journal":{"name":"Perfusion-Uk","volume":" ","pages":"406-416"},"PeriodicalIF":1.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140013533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of percutaneous decannulation and open surgical repair for large-bore arterial access sites of extracorporeal membrane oxygenation. 体外膜肺氧合大口径动脉通路部位的经皮剥离和开放式手术修复比较。
IF 1.1 4区 医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-01 Epub Date: 2024-03-20 DOI: 10.1177/02676591241241609
Alison Y Zhu, Charis Qy Tan, Graham Meredith

Introduction: Following weaning of peripheral venoarterial extracorporeal membrane oxygenation (ECMO) support, removal of cannulas and repair of large-bore arterial sites is traditionally by open surgical repair (OSR). The use of a percutaneous vascular closure device (VCD) offers a minimally invasive alternative to OSR with potential for reduced operative complications, reduced hospital length of stay and in-hospital mortality.

Methods: A systematic review of Medline and Embase databases was conducted for studies comparing VCD-assisted decannulation with OSR following decannulation of peripheral ECMO. The primary endpoint was rate of post-procedural complications, namely wound infection and limb ischaemia. The secondary endpoint was in-hospital mortality.

Results: Eight studies, with a total of 685 patients, met inclusion criteria. Forty-eight percent (n = 328) of patients underwent VCD-assisted decannulation with the remainder decannulated by OSR. Pooled analysis demonstrated that patients undergoing VCD-assisted decannulation are at significantly lower risk of overall complications than surgical repair (OR 4.34; 95% CI 2.19-8.57; p < .001). Specifically, there was a substantial decrease in groin infections (OR 6.77; 95% CI 3.07-14.97; p < .001) without notable differences in limb ischaemia or pseudoaneurysm occurrence between the VCD and OSR cohorts. There was a lower incidence of intra-operative bleeding and haematoma in the VCD cohort (p < .001 and p = .002, respectively).

Conclusion: Vascular closure device-assisted decannulation of peripheral ECMO offers a significantly reduced risk of complications, particularly groin infections and bleeding. Future research should encompass larger cohorts, randomised controlled trials, cost-benefit analyses, and the training of surgeons, cardiologists and intensivists in VCD-assisted decannulation, potentially through the integration of simulation-based training.

导言:断开外周静脉体外膜肺氧合(ECMO)支持后,拔除插管和修复大口径动脉部位的传统方法是开放手术修复(OSR)。经皮血管闭合器(VCD)的使用为开放手术修复提供了一种微创替代方法,有可能减少手术并发症、缩短住院时间并降低院内死亡率:方法: 对 Medline 和 Embase 数据库进行了系统性回顾,比较了外周 ECMO 拔管后 VCD 辅助拔管与 OSR 的研究。主要终点是术后并发症的发生率,即伤口感染和肢体缺血。次要终点是院内死亡率:共有八项研究符合纳入标准,共涉及 685 名患者。48%的患者(n = 328)在 VCD 辅助下进行了封堵,其余患者则通过 OSR 进行了封堵。汇总分析表明,与手术修复相比,接受 VCD 辅助注药的患者发生总体并发症的风险明显较低(OR 4.34; 95% CI 2.19-8.57; p < .001)。具体而言,腹股沟感染大幅减少(OR 6.77;95% CI 3.07-14.97;p < .001),但 VCD 和 OSR 两组患者的肢体缺血或假性动脉瘤发生率没有明显差异。VCD组的术中出血和血肿发生率较低(p < .001 和 p = .002):结论:血管闭合器辅助外周 ECMO 拔管可显著降低并发症风险,尤其是腹股沟感染和出血。未来的研究应包括更大规模的队列、随机对照试验、成本效益分析,以及对外科医生、心脏病专家和重症监护专家进行 VCD 辅助拔管的培训,可能的话可通过整合模拟培训。
{"title":"Comparison of percutaneous decannulation and open surgical repair for large-bore arterial access sites of extracorporeal membrane oxygenation.","authors":"Alison Y Zhu, Charis Qy Tan, Graham Meredith","doi":"10.1177/02676591241241609","DOIUrl":"10.1177/02676591241241609","url":null,"abstract":"<p><strong>Introduction: </strong>Following weaning of peripheral venoarterial extracorporeal membrane oxygenation (ECMO) support, removal of cannulas and repair of large-bore arterial sites is traditionally by open surgical repair (OSR). The use of a percutaneous vascular closure device (VCD) offers a minimally invasive alternative to OSR with potential for reduced operative complications, reduced hospital length of stay and in-hospital mortality.</p><p><strong>Methods: </strong>A systematic review of Medline and Embase databases was conducted for studies comparing VCD-assisted decannulation with OSR following decannulation of peripheral ECMO. The primary endpoint was rate of post-procedural complications, namely wound infection and limb ischaemia. The secondary endpoint was in-hospital mortality.</p><p><strong>Results: </strong>Eight studies, with a total of 685 patients, met inclusion criteria. Forty-eight percent (<i>n</i> = 328) of patients underwent VCD-assisted decannulation with the remainder decannulated by OSR. Pooled analysis demonstrated that patients undergoing VCD-assisted decannulation are at significantly lower risk of overall complications than surgical repair (OR 4.34; 95% CI 2.19-8.57; <i>p</i> < .001). Specifically, there was a substantial decrease in groin infections (OR 6.77; 95% CI 3.07-14.97; <i>p</i> < .001) without notable differences in limb ischaemia or pseudoaneurysm occurrence between the VCD and OSR cohorts. There was a lower incidence of intra-operative bleeding and haematoma in the VCD cohort (<i>p</i> < .001 and <i>p</i> = .002, respectively).</p><p><strong>Conclusion: </strong>Vascular closure device-assisted decannulation of peripheral ECMO offers a significantly reduced risk of complications, particularly groin infections and bleeding. Future research should encompass larger cohorts, randomised controlled trials, cost-benefit analyses, and the training of surgeons, cardiologists and intensivists in VCD-assisted decannulation, potentially through the integration of simulation-based training.</p>","PeriodicalId":49707,"journal":{"name":"Perfusion-Uk","volume":" ","pages":"308-316"},"PeriodicalIF":1.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140177427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel approach to retrograde autologous priming for infant, pediatric and adult populations undergoing congenital heart surgery. 为接受先天性心脏病手术的婴儿、儿童和成人提供逆行自体引流的新方法。
IF 1.1 4区 医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-01 Epub Date: 2024-03-18 DOI: 10.1177/02676591241239820
Joseph Deptula, Vincent Olshove, Molly Oldeen, Deborah Kozik, Bahaaldin Alsoufi

Introduction: Retrograde Autologous Priming (RAP) of cardiopulmonary bypass (CPB) circuits is an effective way to reduce prime volume, commonly through the transfer of prime into separate reservoirs or circuit manipulation. We describe a simple and safe technique for RAP without the need for any circuit modifications or manipulations.

Methods: For this technique, a separate roller pump for ultrafiltration (UF) is used. After adequate heparinization and arterial cannulation, the UF pump is initiated slowly, removing prime through the effluent of the UF, replacing with the patient's blood from the aortic cannula. Once the arterial line and UF circuit are autologous primed, the arterial head displaces reservoir crystalloid toward the UF circuit at a flow rate equal to the UF pump, displacing the crystalloid prime with blood from the UF circuit, autologous priming the boot and oxygenator with blood, crystalloid again being removed by the effluent. After venous cannulation, the venous line prime is replaced with autologous blood, the crystalloid removed by the effluent of the UF circuit via the arterial head. During RAP, if the patient becomes hypovolemic, either autologous volume is transfused back to the patient, or CPB is initiated, without the need for circuitry modifications.

Results: The patient population in this sample consisted of 63 patients ranging between 6.1 kg and 115.6 kg. The smaller the patient, the less blood volume available for RAP and therefore the less prime volume able to be removed. Overall percent removal increases as our patients size increases compared to total circuit volume.

Conclusion: This RAP technique is a safe and effective way to achieve a standardized asanguinous prime for many regardless of patient or circuit size in the absence of contraindications such as low starting hematocrit, emergency surgery or physiologic instability. Most importantly, this potentially reduces the amount of hemodilution patients see from CPB initiation and therefore the lowest nadir hematocrit and consequently the amount of required homologous blood products needed during surgery.

导言:心肺旁路(CPB)回路的逆行自体填料(RAP)是减少填料量的一种有效方法,通常通过将填料转移到单独的储液罐或回路操作来实现。我们介绍了一种简单安全的 RAP 技术,无需对电路进行任何修改或操作:方法:在这一技术中,使用了一个单独的超滤(UF)滚筒泵。在充分肝素化和动脉插管后,缓慢启动超滤泵,通过超滤泵流出的血液去除填料,然后用主动脉插管中的患者血液取而代之。一旦动脉管路和超滤回路完成自体引流,动脉头就会以与超滤泵相同的流速将储存的晶体液置换到超滤回路,用超滤回路的血液置换晶体液引流液,用血液自体引流启动器和氧合器,晶体液再次被流出液移除。静脉插管后,静脉管路的原液由自体血液取代,晶体液由超滤回路的流出液经动脉头排出。在 RAP 过程中,如果患者出现低血容量,要么向患者输回自体血,要么启动 CPB,而无需修改电路:本次抽样调查的患者包括 63 名体重在 6.1 千克到 115.6 千克之间的患者。患者体型越小,可用于 RAP 的血容量越少,因此可移除的原生容量也越少。与回路总容量相比,随着患者体型的增加,移除率也会增加:在没有低起始血细胞比容、急诊手术或生理不稳定等禁忌症的情况下,这种 RAP 技术是一种安全有效的方法,可以为许多人实现标准化的无血供。最重要的是,这有可能减少患者在 CPB 启动时的血液稀释量,从而降低最低原始血细胞比容,进而减少手术过程中所需的同源血制品量。
{"title":"A novel approach to retrograde autologous priming for infant, pediatric and adult populations undergoing congenital heart surgery.","authors":"Joseph Deptula, Vincent Olshove, Molly Oldeen, Deborah Kozik, Bahaaldin Alsoufi","doi":"10.1177/02676591241239820","DOIUrl":"10.1177/02676591241239820","url":null,"abstract":"<p><strong>Introduction: </strong>Retrograde Autologous Priming (RAP) of cardiopulmonary bypass (CPB) circuits is an effective way to reduce prime volume, commonly through the transfer of prime into separate reservoirs or circuit manipulation. We describe a simple and safe technique for RAP without the need for any circuit modifications or manipulations.</p><p><strong>Methods: </strong>For this technique, a separate roller pump for ultrafiltration (UF) is used. After adequate heparinization and arterial cannulation, the UF pump is initiated slowly, removing prime through the effluent of the UF, replacing with the patient's blood from the aortic cannula. Once the arterial line and UF circuit are autologous primed, the arterial head displaces reservoir crystalloid toward the UF circuit at a flow rate equal to the UF pump, displacing the crystalloid prime with blood from the UF circuit, autologous priming the boot and oxygenator with blood, crystalloid again being removed by the effluent. After venous cannulation, the venous line prime is replaced with autologous blood, the crystalloid removed by the effluent of the UF circuit via the arterial head. During RAP, if the patient becomes hypovolemic, either autologous volume is transfused back to the patient, or CPB is initiated, without the need for circuitry modifications.</p><p><strong>Results: </strong>The patient population in this sample consisted of 63 patients ranging between 6.1 kg and 115.6 kg. The smaller the patient, the less blood volume available for RAP and therefore the less prime volume able to be removed. Overall percent removal increases as our patients size increases compared to total circuit volume.</p><p><strong>Conclusion: </strong>This RAP technique is a safe and effective way to achieve a standardized asanguinous prime for many regardless of patient or circuit size in the absence of contraindications such as low starting hematocrit, emergency surgery or physiologic instability. Most importantly, this potentially reduces the amount of hemodilution patients see from CPB initiation and therefore the lowest nadir hematocrit and consequently the amount of required homologous blood products needed during surgery.</p>","PeriodicalId":49707,"journal":{"name":"Perfusion-Uk","volume":" ","pages":"348-353"},"PeriodicalIF":1.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140159381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What is the weakest point of a secured aortic cannula in central extracorporeal membrane oxygenation? 在中心体外膜氧合过程中,固定主动脉插管最薄弱的环节是什么?
IF 1.1 4区 医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-01 Epub Date: 2024-05-28 DOI: 10.1177/02676591241236645
Kayla V Lucas, Yuriy Stukov, Matthew S Purlee, Tatiana Delaleu, Omar M Sharaf, Mark S Bleiweis, Jeffrey Phillip Jacobs, Giles J Peek

Purpose: The purpose of this study was to compare techniques for securing the aortic extracorporeal membrane oxygenation (ECMO) cannula, using in vitro models.

Methods: Two models were studied: a tissue model using porcine aortas and a stand model replacing the aorta with a metal stand to study the system independent of the tissue. Interventions in each model were divided into three experimental groups: Group 1 (3-0 Prolene® + 20-French Medtronic Arterial Cannula EOPA™), Group 2 (4-0 Prolene® + 16-French Medtronic Arterial Cannula DLP Pediatric), and Group 3 (5-0 Prolene® + 8-French Medtronic Arterial Cannula DLP Pediatric). In separate experiments, both gradual and rapid forces were applied to the cannulas, starting with 9.8 Newtons and increasing exponentially if the cannula remained secured. Additionally, the method of securing the tourniquet and the number of ties securing the tourniquet to the cannula were evaluated.

Results: In the tissue model, even with a minimum force of 9.8 Newtons, the suture pulled through the aortic tissue, leaving sutures and ties intact. In the stand model, two purse-string sutures secured by two ligaclips held the cannula reliably and withstood higher total force. Dislodgement was prevented at forces close to 60 Newtons with only two hemostatic clips included in cannulation.

Conclusions: The weakest part of the aortic ECMO cannulation system using in vitro experiments was the tissue. Assuming that these experiments translate in vivo, it is therefore critical to prevent any pull on the cannulas by securing ECMO cannulas and ECMO tubing to both the patient and the patient's bed. Sutures with a larger diameter withstand more force. Two medium hemostatic clips can secure Prolene® sutures within snares as safely as a mosquito hemostat. Two polypropylene purse-string sutures secured by two hemostatic clips were most reliable at greater forces. The rationale for publishing our experiments in this manuscript is to (1) communicate our quantification of possible contributing factors to this rare and likely catastrophic complication of unintended decannulation, (2) increase awareness about this potential complication, and (3) increase vigilance to assure prevention of this dreaded complication.

目的:本研究的目的是利用体外模型比较固定主动脉体外膜肺氧合(ECMO)插管的技术:研究了两个模型:一个是使用猪主动脉的组织模型,另一个是用金属支架代替主动脉的支架模型,以研究独立于组织的系统。每个模型的干预措施分为三个实验组:第 1 组(3-0 Prolene® + 20-French Medtronic Arterial Cannula EOPA™)、第 2 组(4-0 Prolene® + 16-French Medtronic Arterial Cannula DLP Pediatric)和第 3 组(5-0 Prolene® + 8-French Medtronic Arterial Cannula DLP Pediatric)。在不同的实验中,对插管施加了渐进式和快速式两种力,开始时为 9.8 牛顿,如果插管保持固定,则力呈指数增长。此外,还对固定止血带的方法以及将止血带固定在插管上的绑带数量进行了评估:结果:在组织模型中,即使使用最小 9.8 牛顿的力,缝合线也会拉穿主动脉组织,缝合线和绑带完好无损。在支架模型中,由两个结扎夹固定的两条荷包绳缝合线可靠地固定了插管,并承受了更大的总作用力。在插管时只使用两个止血夹,在接近 60 牛顿的压力下也能防止脱落:结论:在体外实验中,主动脉 ECMO 插管系统最薄弱的部分是组织。因此,假定这些实验能在体内转化,那么将 ECMO 插管和 ECMO 管道固定在患者和患者床上,以防止插管受到任何牵拉是至关重要的。直径较大的缝合线可承受更大的拉力。两个中型止血夹可以像蚊香止血钳一样安全地将 Prolene® 缝合线固定在套管内。用两个止血夹固定的两根聚丙烯荷包线缝合线在承受更大的力量时最为可靠。将我们的实验结果发表在本手稿中的目的是:(1) 传播我们对导致意外拔管这种罕见且可能造成灾难性并发症的可能因素的量化结果;(2) 提高对这种潜在并发症的认识;(3) 提高警惕,确保预防这种可怕的并发症。
{"title":"What is the weakest point of a secured aortic cannula in central extracorporeal membrane oxygenation?","authors":"Kayla V Lucas, Yuriy Stukov, Matthew S Purlee, Tatiana Delaleu, Omar M Sharaf, Mark S Bleiweis, Jeffrey Phillip Jacobs, Giles J Peek","doi":"10.1177/02676591241236645","DOIUrl":"10.1177/02676591241236645","url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of this study was to compare techniques for securing the aortic extracorporeal membrane oxygenation (ECMO) cannula, using <i>in vitro</i> models.</p><p><strong>Methods: </strong>Two models were studied: a tissue model using porcine aortas and a stand model replacing the aorta with a metal stand to study the system independent of the tissue. Interventions in each model were divided into three experimental groups: Group 1 (3-0 Prolene<sup>®</sup> + 20-French Medtronic Arterial Cannula EOPA™), Group 2 (4-0 Prolene<sup>®</sup> + 16-French Medtronic Arterial Cannula DLP Pediatric), and Group 3 (5-0 Prolene<sup>®</sup> + 8-French Medtronic Arterial Cannula DLP Pediatric). In separate experiments, both gradual and rapid forces were applied to the cannulas, starting with 9.8 Newtons and increasing exponentially if the cannula remained secured. Additionally, the method of securing the tourniquet and the number of ties securing the tourniquet to the cannula were evaluated.</p><p><strong>Results: </strong>In the tissue model, even with a minimum force of 9.8 Newtons, the suture pulled through the aortic tissue, leaving sutures and ties intact. In the stand model, two purse-string sutures secured by two ligaclips held the cannula reliably and withstood higher total force. Dislodgement was prevented at forces close to 60 Newtons with only two hemostatic clips included in cannulation.</p><p><strong>Conclusions: </strong>The weakest part of the aortic ECMO cannulation system using <i>in vitro</i> experiments was the tissue. Assuming that these experiments translate <i>in vivo</i>, it is therefore critical to prevent any pull on the cannulas by securing ECMO cannulas and ECMO tubing to both the patient and the patient's bed. Sutures with a larger diameter withstand more force. Two medium hemostatic clips can secure Prolene<sup>®</sup> sutures within snares as safely as a mosquito hemostat. Two polypropylene purse-string sutures secured by two hemostatic clips were most reliable at greater forces. The rationale for publishing our experiments in this manuscript is to (1) communicate our quantification of possible contributing factors to this rare and likely catastrophic complication of unintended decannulation, (2) increase awareness about this potential complication, and (3) increase vigilance to assure prevention of this dreaded complication.</p>","PeriodicalId":49707,"journal":{"name":"Perfusion-Uk","volume":" ","pages":"390-397"},"PeriodicalIF":1.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141158695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perfusion education and training in Europe anno 2023. 2023 年欧洲的灌注教育和培训。
IF 1.1 4区 医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-01 Epub Date: 2024-02-27 DOI: 10.1177/02676591241233971
Gerdy Debeuckelaere, Christian Klüß, Katja Ruck, Naveen G Nagaraj, Ermin Brajlović, Gunilla Kjellberg, Cristian Talmaciu, Zvonko Lenart, Monika Muraskauskaite, Nemanja Ristić, Camilla Nyeng, Konstantinos Mintzaridis, Emmanuel Devolder, Radoslav Simeonov, Colin Canavan, Stefan Kmetovski, Tamer Sari, Katerina Krumposova, Maria Teresa Mata, Luka Crnković, Jeffrey Muscat, Normunds Sikora, John Campbell, Markku Rantanen, Inês Figueira, Rein Kruusat, Joël Frédéric, Serhii Sudakevych, Ratko Savović, Andrzej Jelonek, San-Mari van Delft- van Deventer, Maria Erminia Macera Mascitelli

Background: In the absence of uniform European regulations, there have been many differences in the training of perfusionists across Europe. Furthermore, there has been no uniform or single European accreditation of the profession. One of the objectives of The European Board of Cardiovascular Perfusion (EBCP) is to standardise and monitor training of perfusionists across Europe whilst offering support in accordance with national regulations. This goal is particularly imminent as there have been numerous newly founded National perfusion societies, particularly from Eastern European countries, which are now established members of EBCP.Purpose: In this article, we provide an updated overview or 'snapshot' of current European perfusion training programs that were accessible in 2022. Nationally acquired data refers to 2022 unless stated otherwise. The last overview of Perfusion education in Europe was reported over 15 years ago including 20 countries.Research Design: For this report thirty-two national EBCP delegates plus representatives from Austria were contacted at the beginning of 2023 to complete a pro forma questionnaire about their national perfusion training programmes. The data has been summarized in this article and five additional derived parameters were calculated.Results: We received responses from 31 countries, providing specific national training characteristics which are summarized, listed and benchmarked by country in this article.Conclusion: There have been several national and supranational initiatives towards the recognition of perfusion as a profession in Europe, however so far without success for the majority of countries. For this reason, it remains essential for EBCP, as the only European professional perfusionist body, to define education standards and competencies for perfusionists and to monitor training by accreditation of dedicated perfusion schools across Europe.

背景:由于缺乏统一的欧洲法规,欧洲各国在灌注师培训方面存在许多差异。此外,欧洲也没有统一或单一的专业认证。欧洲心血管灌注委员会(European Board of Cardiovascular Perfusion,EBCP)的目标之一就是规范和监督欧洲各国灌注师的培训,同时根据各国法规提供支持。这一目标迫在眉睫,因为许多新成立的国家灌注协会,尤其是东欧国家的灌注协会,现已成为欧洲心血管灌注委员会的正式成员。目的:在这篇文章中,我们提供了当前欧洲灌注培训计划的最新概述或 "快照",这些培训计划在 2022 年可以访问。除非另有说明,否则各国获得的数据均指 2022 年的数据。上一次对欧洲灌注教育的概述是在15年前,包括20个国家:为撰写本报告,我们于 2023 年初联系了 32 位欧洲灌流教育大会(EBCP)的国家代表以及奥地利的代表,让他们填写一份关于本国灌流培训计划的调查问卷。本文对这些数据进行了总结,并计算了另外五个衍生参数:结果:我们收到了来自 31 个国家的回复,这些回复提供了具体的国家培训特点,本文对这些特点进行了总结,并按国家列出和设定了基准:结论:在欧洲,已有多个国家和超国家倡议承认灌注专业,但迄今为止,大多数国家都没有取得成功。因此,作为欧洲唯一的专业灌注师机构,EBCP仍有必要制定灌注师的教育标准和能力要求,并通过对全欧洲的专门灌注学校进行认证来监督培训工作。
{"title":"Perfusion education and training in Europe anno 2023.","authors":"Gerdy Debeuckelaere, Christian Klüß, Katja Ruck, Naveen G Nagaraj, Ermin Brajlović, Gunilla Kjellberg, Cristian Talmaciu, Zvonko Lenart, Monika Muraskauskaite, Nemanja Ristić, Camilla Nyeng, Konstantinos Mintzaridis, Emmanuel Devolder, Radoslav Simeonov, Colin Canavan, Stefan Kmetovski, Tamer Sari, Katerina Krumposova, Maria Teresa Mata, Luka Crnković, Jeffrey Muscat, Normunds Sikora, John Campbell, Markku Rantanen, Inês Figueira, Rein Kruusat, Joël Frédéric, Serhii Sudakevych, Ratko Savović, Andrzej Jelonek, San-Mari van Delft- van Deventer, Maria Erminia Macera Mascitelli","doi":"10.1177/02676591241233971","DOIUrl":"10.1177/02676591241233971","url":null,"abstract":"<p><p><i>Background:</i> In the absence of uniform European regulations, there have been many differences in the training of perfusionists across Europe. Furthermore, there has been no uniform or single European accreditation of the profession. One of the objectives of The European Board of Cardiovascular Perfusion (EBCP) is to standardise and monitor training of perfusionists across Europe whilst offering support in accordance with national regulations. This goal is particularly imminent as there have been numerous newly founded National perfusion societies, particularly from Eastern European countries, which are now established members of EBCP.<i>Purpose:</i> In this article, we provide an updated overview or 'snapshot' of current European perfusion training programs that were accessible in 2022. Nationally acquired data refers to 2022 unless stated otherwise. The last overview of Perfusion education in Europe was reported over 15 years ago including 20 countries.<i>Research Design:</i> For this report thirty-two national EBCP delegates plus representatives from Austria were contacted at the beginning of 2023 to complete a pro forma questionnaire about their national perfusion training programmes. The data has been summarized in this article and five additional derived parameters were calculated.<i>Results:</i> We received responses from 31 countries, providing specific national training characteristics which are summarized, listed and benchmarked by country in this article.<i>Conclusion:</i> There have been several national and supranational initiatives towards the recognition of perfusion as a profession in Europe, however so far without success for the majority of countries. For this reason, it remains essential for EBCP, as the only European professional perfusionist body, to define education standards and competencies for perfusionists and to monitor training by accreditation of dedicated perfusion schools across Europe.</p>","PeriodicalId":49707,"journal":{"name":"Perfusion-Uk","volume":" ","pages":"495-512"},"PeriodicalIF":1.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139974218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Perfusion-Uk
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1